199 related articles for article (PubMed ID: 36359323)
21. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.
Lee SH; Park MJ; Choi SI; Lee EJ; Lee SY; In KH
Medicine (Baltimore); 2017 Jan; 96(4):e5975. PubMed ID: 28121949
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
Kuralay F; Tokgöz Z; Cömlekci A
Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
[TBL] [Abstract][Full Text] [Related]
23. Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions.
Wang M; Zhang Z; Wang X
Clinics (Sao Paulo); 2014; 69(12):799-803. PubMed ID: 25627990
[TBL] [Abstract][Full Text] [Related]
24. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
[TBL] [Abstract][Full Text] [Related]
25. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
Creaney J; Yeoman D; Naumoff LK; Hof M; Segal A; Musk AW; De Klerk N; Horick N; Skates SJ; Robinson BW
Thorax; 2007 Jul; 62(7):569-76. PubMed ID: 17356060
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
28. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
Gueugnon F; Leclercq S; Blanquart C; Sagan C; Cellerin L; Padieu M; Perigaud C; Scherpereel A; Gregoire M
Am J Pathol; 2011 Mar; 178(3):1033-42. PubMed ID: 21356356
[TBL] [Abstract][Full Text] [Related]
30. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
31. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
32. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
33. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
[TBL] [Abstract][Full Text] [Related]
35. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
36. Profile of soluble factors in pleural effusions predict prognosis in mesothelioma.
Dick IM; Lee YCG; Cheah HM; Miranda A; Robinson BWS; Creaney J
Cancer Biomark; 2022; 33(1):159-169. PubMed ID: 34487023
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
[TBL] [Abstract][Full Text] [Related]
39. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
Lung; 2017 Oct; 195(5):653-660. PubMed ID: 28656381
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels.
Saraya T; Ohkuma K; Fujiwara M; Ishii H
Medicine (Baltimore); 2022 Jan; 101(1):e28517. PubMed ID: 35029914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
